Cipla's US recovery now rests on a new plant and three FDA decisions

Cipla sold $172 million of medicines in the US in the September 2026 quarter, up from the quarter before. It kept its guidance to leave this financial year with US sales running at $1 billion a year. Divided by four, that run rate means about $250 million a quarter, more than the $233 million the US business earned a year ago, before sales there fell. Last quarter's figure was a recovery; reaching the guide means going beyond where the business stood before its fall.

The guide has kept its number while changing its meaning. In July 2025 management described its pipeline as taking US revenue close to or past that figure in this financial year. In May 2026, with quarterly US sales down to $155 million, it said the figure was a run rate at the end of the year, not revenue during it. Two quarters into that year, the business needs about $78 million more of quarterly sales, calculated from last quarter's figure and the implied target.

Part of that climb rests on products Cipla already has. Its generic versions of Ventolin, an asthma rescue inhaler, and Advair, a dry-powder inhaler, are both approved, and management expects the two to contribute significantly. Both are made at the company's new US plant, and the plant has set the pace. Management said Ventolin sales depend on the plant raising supply. Advair, the first dry-powder product from that site, is launching only this quarter, a couple of months after approval, a delay management put down to the plant being new.

The rest depends on decisions by the US Food and Drug Administration: two respiratory products and a peptide drug are still awaiting approval. Management expects them within the financial year, adding: "The exact dates are not 100% in our control, so we announce them as soon as they get approved." Asked how much of the climb would come from each product, it said the mix depends on when the approvals arrive.

The plant's early problems may not repeat. One of the two pending respiratory products is a partner's, made at Cipla's Goa site, which management said already has experience making such inhalers, so it should need no ramp-up; the other would come from the US plant. Management said the delays with Ventolin and Advair came from their being the first launches from those units, and that it does not expect the same trouble with later ones.

The margin guidance leans on the same climb. Cipla's EBITDA margin, a profit measure before depreciation and amortisation that here also excludes other income, was 18.7% last quarter, up from 16.7% the quarter before and from a low of 15.2% the quarter before that, though still below the 25.0% of a year ago. The company kept its full-year range of 18.5% to 20%. Weighted by revenue, the first half averaged about 17.7%, calculated from the two quarters' reported margins and sales, so the second half has to run above the bottom of the range.

Management tied the expected improvement to the US ramp-up. The costs are already showing: total expenses rose from the quarter before, which the company put down to spending on upcoming launches and on readying its plants. India gives some room. The One India business grew 12% from a year earlier, and management said a swing in North American sales moves that region's EBITDA more than India's.

The US guide reads as it did in May. What has changed is that the launch spending is in the accounts and half the year has passed with US sales still well short of the implied target. Both numbers now ride on how fast the new US plant ships Ventolin and Advair, and on when the FDA rules on the three pending products.